Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Stock Price: $52.87
+0.7 (1.34%)
Updated Feb 2, 2023 09:00 PM GMT+0000
Featured app
eToro
Invest now
<p>79% of retail CFD accounts lose money</p>
Overview
Financials
Statistics
Profile
Chart
Market Cap 7.15B
Revenue 580.62M
Gross Profit 461.85M
Shares Out 135.21M
EPS (ttm) 1.49
PE Ratio 33.8486
Forward PE 16.9130
Dividend Rate (ttm) 0.0000
Dividend Yield 0.0000
Trading Day Feb 2
Last Price $52.87
Previous Close $52.17
Change ($) 0.7
Change (%) 1.34%
Day's Open 52.17
Day's Range Market Closed
Day's Volume 1.09M
52 Week Range 32 - 59.46

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company focused on bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success.

Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx and Horizon Therapeutics.

Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company's partners make progress developing and commercializing their products being developed with ENHANZE®. Halozyme is headquartered in San Diego.

News

Quick info

Country
United States
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Employees
145
CEO
Helen Torley
Address
11388 Sorrento Valley Rd
San Diego
California
92121-1345
Phone
18587948889
Ticker Symbol
HALO
Reporting Currency
USD